1. Home
  2. KRNY vs BWAY Comparison

KRNY vs BWAY Comparison

Compare KRNY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

N/A

Current Price

$9.18

Market Cap

581.2M

Sector

Finance

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$12.63

Market Cap

547.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRNY
BWAY
Founded
1884
2003
Country
United States
Israel
Employees
549
N/A
Industry
Savings Institutions
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
581.2M
547.7M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
KRNY
BWAY
Price
$9.18
$12.63
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$10.67
★ $19.27
AVG Volume (30 Days)
★ 401.0K
77.2K
Earning Date
10-22-2026
11-10-2026
Dividend Yield
★ 4.80%
N/A
EPS Growth
★ 35.71
N/A
EPS
★ 0.57
N/A
Revenue
★ $2,580,000.00
N/A
Revenue This Year
$11.95
$32.42
Revenue Next Year
$11.09
$23.40
P/E Ratio
★ $16.04
$81.98
Revenue Growth
★ 36.00
N/A
52 Week Low
$6.23
$11.77
52 Week High
$10.24
$26.63

Technical Indicators

Market Signals
Indicator
KRNY
BWAY
Relative Strength Index (RSI) 32.03 31.45
Support Level $9.05 $11.90
Resistance Level $9.74 $14.83
Average True Range (ATR) 0.19 0.55
MACD -0.07 -0.02
Stochastic Oscillator 9.95 0.61

Price Performance

Historical Comparison
KRNY
BWAY

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income from their clients.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: